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CASE REPORT
Pleomorphic liposarcoma of bone: a rare 
primary malignant bone tumour
G. L. Tiemeier1, J. M. Brown1, S. E. Pratap2, C. McCarthy3, A. Kastrenopoulou1, K. Bradley4, S. Wilson2, Z. Orosz1, 
C. L. M. H. Gibbons2, U. Oppermann1 and N. A. Athanasou1*
Abstract 
Background: Liposarcoma is an extremely rare primary bone sarcoma.
Case presentation: We report a case of primary pleomorphic liposarcoma that arose in an 18 year old male in the 
metaphysis of the left tibia. Plain radiographs showed a partly sclerotic lesion and MR imaging a heterogeneous 
tumour predominantly isointense on T1- and high-signal on T2-weighted sequences with focal areas of increased T1 
signal that suppressed with fat saturation. PET/CT showed marked FDG uptake (SUV = 17.1) in the primary tumour as 
well as a metastasis in the right distal femur and multiple small pulmonary metastases. Histologically, the tumour was 
a pleomorphic liposarcoma containing large tumour cells with vacuolated cytoplasm and hyperchromatic pleomor-
phic nuclei as well as numerous lipoblasts and scattered brown fat-like cells. Tumour cells strongly expressed FABP4/
aP2, a marker of adipocyte differentiation, and UCP1, a marker of brown fat, but not S100. The case was treated with 
neoadjuvant MAP chemotherapy, resulting in extensive (> 95%) necrosis in the primary tumour and almost complete 
resolution of the femoral and pulmonary metastases.
Conclusions: Pleomorphic liposarcoma can present as a sclerotic primary malignant bone tumour; markers of 
adipose differentiation are useful in histological diagnosis and neoadjuvant MAP chemotherapy results in significant 
tumor necrosis.
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Background
Liposarcoma is an extremely rare primary malignant 
bone tumour defined in the 2005 AFIP Fascicle as “A 
malignant tumor with differentiation towards adipo-
cytes” [1]. Catto and Stevens [2], reviewing the world 
literature in 1963, could find only 15 cases of primary 
bone liposarcoma; they noted that most reported cases 
were pleomorphic sarcomas and considered only one 
case, that reported by Dawson in 1955 [3], as completely 
convincing. In 1982 Addison and Payne accepted only six 
examples of this tumour in previously published reports 
[4]. Subsequently, other cases have been reported, but 
there is considerable uncertainty regarding the histologi-
cal diagnosis and optimum treatment of this rare tumour.
We report the clinical, radiological (including MRI and 
PET/CT) and pathological findings in a case of primary 
pleomorphic liposarcoma that arose in the proximal 
tibia of an 18  year old male. We also review the litera-
ture regarding primary liposarcoma of bone and reassess 
diagnostic criteria and treatment options in the light of 
our findings.
Case presentation
An 18 year old white male presented with a 6 month his-
tory of discomfort and swelling in his left knee. An X-ray 
and MRI of the left knee revealed a large, partly miner-
alized tumour in the medial tibial diaphysis. In his past 
history, the patient had been diagnosed at birth with 
coarctation of the aorta and primary lymphoedema. Bal-
loon dilatation angioplasty was successfully performed 
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on day 13 of life. Subsequent cardiac medical manage-
ment included nifedipine between the ages of 4 and 9; 
this was later switched to atenolol because of lymphoe-
dema. His phenotype was consistent with a variant of 
Irons–Bianchi syndrome or ‘‘Milroy-like’’ lymphoedema. 
Further details of his medical history and treatment 
are described elsewhere [5]. Genetic testing to date has 
proven negative for pathogenic variants, including the 
“Red Cell gene panel” and the 23 genes in the “Rasopa-
thy panel” although heterozygous variations of uncertain 
clinical significance were identified in the FAT4 gene 
(c.8290A  >  C and c.12070C  >  T). He had also received 
topical bleomycin and acitretin for persistent plantar 
viral warts. The patient had no family history of congeni-
tal syndromes, but there was a strong family history of 
cancer including renal cell carcinoma, skin cancer, bowel 
cancer and breast cancer in second-degree relatives.
Radiological findings
Plain radiographs demonstrated a poorly defined, per-
meative, radiolucent lesion, centred in the proximal tib-
ial meta-diaphysis. A pathological fracture was present 
(Fig. 1).
There was postero-medial cortical destruction with 
adjacent areas of ossification. There was evidence of low 
density in the medial soft tissue mass, raising the possi-
bility of a fatty matrix.
Magnetic resonance imaging (MRI) showed that the 
tumour filled the medullary cavity of the proximal tibial 
metaphysis; it had an ill-defined margin and crossed the 
physis extending to the subarticular surface but there was 
no intra-articular extension (Fig.  2). Extensive medial 
cortical destruction was associated with an almost cir-
cumferential spiculated soft tissue mass which had dis-
placed the calf musculature and popliteal neurovascular 
bundle. The tumour breached the deep fascia and the 
interosseous membrane. The lesion was of heterogeneous 
isointense signal on T1- and high signal on T2-weighted 
images. Areas of high T1 signal suppressed on fat satura-
tion sequences, supporting a partly fatty matrix. A patho-
logical fracture was clearly seen extending transversely 
across the proximal tibia.
Positron emission tomography with fluorodeoxy-
glucose (FDG) integrated with computed tomography 
(PET/CT) confirmed an ill-defined proximal tibial lesion 
with medial cortical destruction and a large soft tissue 
mass containing areas of fat attenuation and ossification 
(Fig. 3a). The tumour showed marked FDG uptake with 
a standardised uptake value (SUV) of 17.1 and a band 
of relative photopaenia in the region of the undisplaced 
transverse pathological fracture. A further focus of mark-
edly increased FDG uptake with an SUV of 13.5 was seen 
in a lateral distal femoral lesion which was presumed to 
represent a metastasis (Fig. 3b). Eight small bilateral pul-
monary nodules (maximum 4  mm) were also noted on 
the PET/CT scan consistent with lung metastases. There 
was no lymphadenopathy, and no fat or other soft tissue 
lesion was noted.
Histological findings
Histology of a biopsy of the tibial mass revealed a prolif-
eration of malignant cells that had vacuolated cytoplasm 
and large atypical pleomorphic nuclei (Fig. 4). There were 
vacuolated tumour giant cells and numerous small lipo-
blast-like cells with a single cytoplasmic fat vacuole and 
hyperchromatic nuclei as well as brown fat-like cells with 
multiple small fat vacuoles (Fig.  4a, b). There were fre-
quent mitotic figures, many of which were atypical. No 
evidence of osteoid formation was seen. There was infil-
tration of cancellous bone and evidence of lymphovas-
cular invasion. Immunohistological analysis showed that 
the malignant cells strongly expressed FABP4/aP2 [6, 7], 
a marker of adipocyte differentiation and UCP1 [8–10], a 
marker of brown adipose tissue (Fig. 4c, d); there was no 
expression of S100, desmin, smooth muscle/muscle actin, 
myogenin, CD34, CD31, CD30, CD45, cytokeratin, epi-
thelial membrane antigen, CD99 or CD117. Cytogenetic 
analysis showed that there was no evidence of MDM2 or 
CDK4 amplification. The morphological and immunohis-
tochemical features were thought to be most in keeping 
Fig. 1 a AP and lateral b plain radiographs demonstrate an ill-
defined radiolucent lesion in the proximal tibial metadiaphysis (black 
arrows) with posteromedial cortical destruction and adjacent ossifica-
tion (black arrowheads). A medial soft tissue mass with low density 
raises the possibility of a fatty matrix (white arrow). A pathological 
fracture is present (white arrowhead)
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with a diagnosis of primary pleomorphic liposarcoma of 
bone.
Oncological and surgical treatment
The patient was treated with two cycles of neoadjuvant 
multi-agent chemotherapy, comprising methotrex-
ate, doxorubicin and cisplatin (MAP), as per the closed 
European American Osteosarcoma (EURAMOS) trial. 
His baseline pre-treatment 2D transthoracic echocardio-
gram was within normal limits with an ejection fraction 
of 70%. The patient tolerated the chemotherapy well with 
clinical improvement after 2 cycles of chemotherapy as 
evidenced by a significant reduction in his analgesia use. 
The preoperative MRI showed an interval reduction of 
the large primary left tibial lesion but an increase in size 
and interval of the right distal femoral lesion. The pre-
operative PET scan demonstrated a discordant excellent 
metabolic response to neoadjuvant chemotherapy within 
both the primary tumour and the metastatic lesions. The 
FDG uptake was significantly reduced in the primary 
tumour of the tibia from 17.1 to 2.7 and the focus in the 
femur and right tibia showed only background activity. 
Fig. 2 Magnetic Resonance Imaging (MRI) of the proximal tibial lesion. a Coronal STIR, b coronal T1-, c axial T1-, d axial T2-weighted and, e axial pro-
ton density with fat saturation. The images demonstrate an ill-defined proximal tibial medullary based lesion extending to the subarticular surface. 
There is extensive cortical destruction with an almost circumferential soft tissue mass, which has a spiculated appearance (black arrows) displacing 
the posterior muscles and popliteal neurovascular bundle. Tumour breaches the deep fascia anteriorly to extend into the subcutaneous tissues and 
penetrates the interosseous membrane to extend around the anterolateral tibial cortex. Heterogeneous partly high T1 signal suppresses with fat 
saturation sequences supporting a partly fatty matrix (white arrowheads). The pathological fracture is clearly seen extending transversely across the 
proximal tibia (white arrows)
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The majority of the bilateral pulmonary nodules had also 
resolved.
The patient underwent an uncomplicated surgical 
resection of the primary tumour in the proximal tibia and 
the lesion in the distal femur with reconstruction using 
a linked distal femur and proximal tibial endoprosthe-
sis (Stanmore Implants, UK) (Fig.  5). At operation, the 
left proximal tibial tumour was noted to be yellow and 
necrotic; it filled the medullary cavity and had spread 
through the bone cortex into covering soft tissues. A sec-
ond yellow nodule was present in the left distal femur. 
Histologically, the resected tibia contained only a small 
amount of residual viable tumor that was similar mor-
phologically and immunohistochemically to that seen in 
the biopsy. There was extensive (> 95%) tumor necrosis as 
a consequence of neoadjuvant chemotherapy.
Post-operative adjuvant chemotherapy was considered 
appropriate in this case because of the excellent response 
to chemotherapy. As routine cardiac assessment demon-
strated an asymptomatic significant reduction in ejection 
fraction (70–53%), adjuvant chemotherapy was changed 
to 5 cycles of ifosfamide and etoposide, because of the 
previously reported activity of ifosfamide in liposar-
coma [11]. 12 months after surgical excision of the tibial 
and femoral lesions, the patient is well with no evidence 
of metastasis or recurrence on clinical and radiological 
(including PET scan) follow up.
Discussion
Although liposarcoma is a relatively common malignant 
soft tissue tumour, it has only rarely been reported in 
bone (Table 1). In most of these reports, the tumour was 
simply described as a primary bone sarcoma containing 
numerous vacuolated pleomorphic tumour cells with the 
tumour considered to represent a liposarcoma mainly on 
cytomorphological grounds [2–4, 12–29]. Several of these 
reports have been questioned on the basis of histological 
interpretation and uncertainty as to whether the lesion 
was entirely located within bone. In more recent reports, 
five such tumours have been specifically designated as 
pleomorphic liposarcomas [30–34]. In the majority of 
reported cases, liposarcoma of bone has been noted to 
develop in major long tubular bones including femur, tibia 
and humerus with most cases located in the lower limb. 
The tumour has been reported to occur over a wide age 
range (13–69 years), with an average age of 38 years; only 
six of the cases previously reported occurred in patients 
under the age of 25 years. In our case, the tumour arose in 
the proximal tibia of an 18 year old male.
In most previous reports, plain radiographs of primary 
liposarcoma of bone have shown an ill-defined osteolytic 
lesion, but sclerotic areas have also been noted [4, 21, 
22, 25, 32]. In this case, the tumour contained spiculated 
areas of ossification with evidence of cortical destruction 
and a soft tissue mass. These features suggested osteoid/
bone formation and the favored radiological diagno-
sis pre-biopsy was osteosarcoma. MRI showed that the 
lesion was of heterogeneous isointense signal on T1- and 
high signal on T2-weighted sequences respectively. Areas 
of high T1 signal suppressed with fat saturation, support-
ing a partly fatty matrix. Heterogeneous hyper-intensity 
Fig. 3 Axial CT and PET/CT imaging of the proximal tibial lesion. a 
Axial CT imaging shows medial cortical destruction and a large soft 
tissue mass containing areas of fat attenuation (white arrowheads) 
and ossification (black arrows). b A coronal fused PET/CT image 
shows there is marked FDG uptake in the proximal tibial tumour as 
well as in a lateral distal femoral metastasis (white arrow). No other 
lipomatous lesion or tumour is present
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on T1 and T2-weighted images has been described 
in previous case reports [32, 34]. Haemorrhage could 
account for high T1 and T2 signal areas but, in our case 
methaemoglobin did not suppress with fat saturation.
Our case showed typical histological features of pleo-
morphic liposarcoma. There were numerous small and 
large lipoblasts as well as many large tumour cells with 
vacuolated cytoplasm and highly pleomorphic nuclei; in 
addition, there were many brown fat-like cells with atypi-
cal large hyperchromatic nuclei. Tumour cells strongly 
expressed FABP4/aP2, a marker of adipose differentia-
tion [6], and UCP1, a marker of brown fat cells [8–10]. 
FABP4/aP2 has consistently been shown to be expressed 
in soft tissue tumours of adipose differentiation and is 
useful in distinguishing primary pleomorphic liposar-
coma from other soft tissue pleomorphic sarcomas [6]. 
FABP4/aP2 is also expressed by brown and white fat 
cells in hibernoma of bone [7]. In our case, expression 
of FABP4/aP2 was useful in confirming the morphologi-
cal diagnosis of primary pleomorphic liposarcoma and 
Fig. 4 Histological analysis of the proximal tibial lesion shows primary pleomorphic liposarcoma of bone. a The tumor infiltrates cancellous bone 
and is composed of numerous lipoblasts and large pleomorphic cells, which have vacuolated cytoplasm and atypical nuclei. b Lipoblasts and 
brown fat-like cells are seen within the tumour. Immunohistochemistry shows the tumor cells express FABP4/aP2 (c) and UCP1 (d)
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excluding osteosarcoma and un-differentiated pleomor-
phic sarcoma, both of which are FABP4/aP2 negative [6]. 
Expression of UCP1 was consistent with the finding of 
numerous brown fat–like cells within the tumour. UCP1 
was also expressed by lipoblasts in the tumour. Our case 
did not show tumour cell expression of S100 or evidence 
of MDM2/CDK4 amplification. Absence of S100 has 
been noted in more than 50% of soft tissue pleomorphic 
liposarcomas in which MDM2 and CDK4 amplification is 
also typically absent [35].
Most previously reported intraosseous liposarco-
mas have been noted to exhibit morphological fea-
tures in keeping with the pleomorphic liposarcoma 
subtype. However, other high-grade primary malignant 
tumours containing liposarcomatous elements have been 
described in bone. These include a liposarcoma contain-
ing osteosarcomatous foci [25], a mesenchymoma of 
bone showing liposarcomatous features [36] and a pri-
mary dedifferentiated liposarcoma of the femur that pre-
sented as a malignant fibrous histiocytoma [29]. Downey 
et al. [25] specified that several criteria must be met for 
the acceptance of a diagnosis of a primary intraosseous 
liposarcoma of bone. First, it must be proved that the 
tumour has arisen primarily within the bone i.e. that it 
is not a metastatic deposit and that it is not periosteal 
in origin, involving the cortex and marrow secondarily. 
In addition, a predominance of immature pleomorphic, 
often bizarre, uni-globular and multi-globular lipoblasts 
should be noted histologically. Our case meets these 
criteria, having arisen within the tibia and containing 
numerous vacuolated tumor cells including lipoblasts. It 
should be noted that the WHO definition of liposarcoma 
of bone does not exclude origin from the bone surface 
[37]; it specifies that the tumour is “a malignant neoplasm 
whose phenotype recapitulates fat and arises within or on 
the bone surface.” Based on the findings in the present 
case, we propose that immunophenotypic expression of 
markers of adipocyte differentiation (i.e. FABP4/aP2 and 
UCP1) could usefully be added to the list of criteria for 
the diagnosis of primary liposarcoma of bone.
Outcome following surgery alone of primary lipo-
sarcoma of bone is relatively poor, and there is little 
data on the use of adjuvant or neoadjuvant chemother-
apy or radiotherapy. A review of the literature shows 
that 16 patients (55%) died after a mean of 13 (range, 
½–36)  months, whereas 11 (38%) were alive at a mean 
follow-up of 28 (range 5–60) months (Table 1). Only five 
cases were treated with chemotherapy. In one case neo-
adjuvant MAP chemotherapy resulted in 54% tumour 
necrosis; after surgery the treatment was switched to 
ifosfamide and etoposide with no recurrence reported 
after 13  months follow-up [18]. Torigoe et  al. reported 
no effect of high dose ifosfamide; a change to cispl-
atin and doxorubicin resulted in liver toxicity and dete-
rioration [32]. Macmull et  al. [28] found no effect with 
doxorubicin, and when chemotherapy was changed to 
ifosfamide and etoposide no relapse after 16 months fol-
low up. In a further two cases treated with chemotherapy, 
there was no reported efficacy, both patients dying within 
1.5  years of follow-up [19, 20]. There is now discussion 
within the sarcoma community that rare high-grade pri-
mary malignant bone tumours should have their chemo-
therapy tailored according to their individual histological 
subtype [38, 39]. In our case neoadjuvant MAP treatment 
resulted in an unexpectedly good tumour response after 
two cycles, with background FDG signal of the meta-
static sites of disease and more than 95% necrosis in the 
primary tumor noted after surgery. Pleomorphic liposar-
coma of bone is rare tumour and there is no clinical trial 
data available to guide the optimal chemotherapeutic 
Fig. 5 Post-resection AP plain radiograph demonstrates a Stanmore 
prosthesis with integral distal femur and modular proximal tibial 
component
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approach. Treatment findings in our case provide some 
support for the use for neoadjuvant MAP chemotherapy 
to treat this rare tumour.
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